Beschreibung:
<jats:title>Abstract</jats:title>
<jats:p>One of the driving forces in personalized medicine is the search for protein patterns that can be utilized for improved diagnosis, assessing the risk for tumor relapse and disease progression. Affinity proteomics, a high-throughput technology for protein expression profiling, is now generating data for improved diagnosis and patient stratification, which has been demonstrated in several clinical studies. Pancreatic ductal adenocarcinoma (PDAC) is such a disease where detection preceding clinical symptoms significantly increases the life expectancy of patients. Based on multiparametric microarray analysis of over 2500 patient samples, serum protein signatures have for the first time been identified that could discriminate between pancreatic cancer patients with stage I, II, III and IV, which indicates a possibility for early diagnosis and an increased detection rate of surgically resectable tumors, which significantly would increase the life expectancy of pancreatic cancer patients.</jats:p>
<jats:p>Citation Format: Carl A. K. Borrebaeck.{Authors}. Serum contains enough information for early detection of pancreatic cancer. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2016 May 12-15; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2016;76(24 Suppl):Abstract nr IA06.</jats:p>